Communiqués ACADIA Pharmaceuticals Inc.

Actions

ACAD

US0042251084

Recherche biotechnologique et médicale

Temps réel estimé Cboe BZX 17:05:02 31/08/2026			Varia. 5j.	Varia. 1 janv.
28,64 ^USD	-1,63%		-3,34%	+7,30%

25/08	ACADIA Pharmaceuticals Inc. : Deutsche Bank Securities maintient sa recommandation à l'achat	ZM
25/08	L'Union européenne approuve le Daybu, médicament d'Acadia Pharmaceuticals contre le syndrome de Rett	MT

Communiqués

24/08	European Commission Approves DAYBU® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union	BU
24/08	La Commission européenne a approuvé DAYBU® (trofinetide), le premier et unique traitement des symptômes neurocomportementaux du syndrome de Rett au sein de l’Union européenne	BU
04/08	Acadia: Q2 Earnings Snapshot	AQ
04/08	Acadia Pharmaceuticals Reports Second Quarter 2026 Financial Results	BU
20/07	Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis	BU
15/07	Acadia Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 4, 2026	BU
06/07	Acadia Pharmaceuticals Appoints Carl Segerstrom as Chief People Officer	BU
26/06	DAYBU® (trofinétide) recommandé dans l’UE par le CHMP pour le traitement du syndrome de Rett	BU
26/06	DAYBU® (trofinetide) Recommended for Approval in the European Union by CHMP	BU
06/05	Acadia: Q1 Earnings Snapshot	AQ
06/05	Acadia Pharmaceuticals Reports First Quarter 2026 Financial Results and Reaffirms 2026 Financial Guidance	BU
30/04	Acadia Pharmaceuticals Announces Planned Year-End Retirement of Elizabeth H.Z. Thompson, Ph.D., Head of Research and Development, Following a Distinguished Career	BU
28/04	Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences	BU
20/04	Acadia Pharmaceuticals to Present Data at the 2026 American Academy of Neurology Annual Meeting	AQ
17/04	Acadia Pharmaceuticals to Present Data at the 2026 American Academy of Neurology (AAN) Annual Meeting	BU
15/04	Acadia Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 6, 2026	BU
07/04	Acadia Pharmaceuticals Announces DAYBUE® STIX (trofinetide) is Now Broadly Available in the United States for the Treatment of Rett Syndrome	BU
12/03	Acadia Pharmaceuticals to Participate in the Stifel 2026 Virtual CNS Forum	BU
03/03	Acadia Pharmaceuticals Appoints Jonathan M. Poole to its Board of Directors	BU
02/03	Acadia Pharmaceuticals Announces Plan to Request Re-Examination Following Negative CHMP Opinion for Trofinetide for the Treatment of Rett Syndrome	BU
25/02	Acadia: Q4 Earnings Snapshot	AQ
25/02	Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operating Overview	BU
23/02	Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences	BU
04/02	Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026	BU
02/02	Acadia Pharmaceuticals Provides Update on Regulatory Submission for Trofinetide for the Treatment of Rett Syndrome in the European Union	BU